Generex Biotechnology granted Canadian patent

Generex Biotechnology Corporation has announced that it has been granted a patent by the Canadian Intellectual Property Office titled "Mixed Micellar Delivery System and Method of Preparation."

This patent, an extant United States Patent registered by the Company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals, particularly through the oral and nasal membranes.

The patent covers formulations for the delivery of peptidic drugs, vaccines, and hormones and enhances the Company's existing drug delivery platform patent portfolio.

"Generex welcomes this Canadian patent as we proceed along the path to later stage trials in Canada. We are pleased that our patent portfolio has been expanding internationally and the grant of this Canadian patent is of particular importance as it has strengthened the protection of our flagship oral insulin product, Oral-lyn (TM), in the birthplace of insulin," said Rose Perri, the Company's Chief Operating Officer.

The Company currently holds an aggregate of 70 patents (17 of which are United States patents) and has an aggregate of 60 patent applications pending in various jurisdictions.